VR
Vijayabhaskar Reddy Kandula
About Vijayabhaskar Reddy Kandula
Data last updated:
Vijayabhaskar Reddy Kandula is a Director at Medtherapy Biotechnology (India) Private Limited (since 2020) and Director at Global Center For Gene Therapies Foundation (since 2025). The companies operate in Pharma and Professional Services. The largest current company by reported revenue is Medtherapy Biotechnology (India) Private Limited at ₹5.18 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 18 Feb 2020 | 2020 | ₹5.18 Cr (FY 2025) | Active | |
| Director | 13 Jan 2025 | 2025 | Active |
Board colleagues of Vijayabhaskar Reddy Kandula
| Name | DIN | Company | Designation |
|---|---|---|---|
| Bikash Kumar Verma | 08702731 | Medtherapy Biotechnology (India) Private Limited , Global Center For Gene Therapies Foundation | Director |
| Sanjay Kumar Singh | 02755503 | Global Center For Gene Therapies Foundation | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Vijayabhaskar Reddy Kandula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vijayabhaskar Reddy Kandula
Vijayabhaskar Reddy Kandula currently holds 2 directorships: Medtherapy Biotechnology (India) Private Limited (Director, since 18 Feb 2020, revenue ₹5.18 Cr (FY 2025)); Global Center For Gene Therapies Foundation (Director, since 13 Jan 2025).
Vijayabhaskar Reddy Kandula was first appointed on 18 Feb 2020 as Director at Medtherapy Biotechnology (India) Private Limited. The most recent appointment on record is 13 Jan 2025 at Global Center For Gene Therapies Foundation.
The current boards of Vijayabhaskar Reddy Kandula's companies include Bikash Kumar Verma (Medtherapy Biotechnology (India) Private Limited), Sanjay Kumar Singh (Global Center For Gene Therapies Foundation).